National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years. - A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers.
CD8+ young TIL; Aldesleukin; Cyclophosphamide; Fludarabine
Memorial Sloan-Kettering Cancer Center - Recruiting 21 years or older. - A Prospective Trial to Evaluate Whether Variations in Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy.
Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older. - A Phase II Study of Afatinib (BIBW 2992) in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer.
Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older. - Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites..
Novartis - Recruiting 18 years or older. - A Phase IB, Multicenter, Open-label Dose Escalation Study of the PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Carrying a Molecular Alteration of PIK3CA or an Amplification of HER2.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years. - Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes.
Hoffmann-La Roche - Recruiting 18 years to 75 years. - Safety and Tolerability of Oxaliplatin-Capecitabine-Trastuzumab Combination and Chemoradiotherapy in Adjuvant Setting in Operated HER2+ Patients With Gastric or Gastroesophageal Junction Adenocarcinoma: A Phase II Study (TOXAG Study).
Survey of client health, personal habits, family history; Blood specimen for non-DNA and DNA parts; Biopsy of esophageal/stomach tissue, lymph nodes, tumor; Biopsies from routine clinical surveillance endoscopies
Amgen - Recruiting 18 years or older. - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older. - Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum.
Bristol-Myers Squibb - Recruiting 18 years or older. - A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer.
Case Comprehensive Cancer Center - Recruiting 18 years or older. - A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older. - Epigenetically-Modified Autologous Tumor Cell Vaccines With ISCOMATRIX(TM) Adjuvant and Oral Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas.
Southwest Oncology Group - Recruiting 18 years or older. - A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer.
Dekkun Corporation - Recruiting 30 years or older. - A Two Part, Phase 1, Multi-Center, Open-Label Study of DKN-01 in Combination With Weekly Paclitaxel in Patients With Relapsed or Refractory Esophageal Cancer or Gastro-Esophageal Junction Tumors.
Foundation for Liver Research - Recruiting 18 years or older. - A Randomized Comparison of a Fully Covered Self Expandable Metal Stent Versus a Partially Covered Self Expandable Metal Stent in Malignant Esophageal Strictures.
Xijing Hospital of Digestive Diseases - Recruiting 18 years to 80 years. - Comparison of O-type Hybrid Knife and IT Knife in Endoscopic Submucosal Dissection for Upper Gastrointestinal Neoplasms: a Prospective Randomized Controlled Trial.
Chinese Academy of Medical Sciences - Recruiting 18 years or older. - Pase 2 Study of Albumin-bounded Paclitaxel Plus S-1 as First-line Chemotherapy for Locally Advanced or Metastatic Gastric or Gastro-esophageal Adenocarcinoma.
National Taiwan University Hospital - Recruiting 20 years to 90 years. - Serum Biomarker Study for the Prognosis of Patients With Hepatocellular Carcinoma and Esophageal Cancer Undergoing Radiotherapy Using Multiplex Proximity Ligation Assay.
National Cancer Institute (NCI) - Recruiting 20 years to 74 years. - An Investigational Study of Chemoradiosensitivity Prediction With Genetic Profiling of Esophageal Biopsy for Squamous Cell Carcinoma of the Esophagus.
National Cancer Institute (NCI) - Recruiting N/A or older. - Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation.
18F-fluoromisonidazole; fluorescence angiography; laboratory biomarker analysis; infrared thermography; magnetic resonance imaging; therapeutic conventional surgery; [18F]-ML-10; fludeoxyglucose F 18; rubidium Rb-82
University Hospitals, Leicester - Recruiting 18 years or older. - Phase II Trial of Palliative Epirubicin, Oxaliplatin & Capecitabine (EOX) Chemotherapy Combined With Omega-3 Fish Oil Infusion (Omegaven) in Patients With Oesophagogastric Carcinoma.
Zhejiang Cancer Hospital - Recruiting 18 years to 65 years. - Prospective Randomized Phase ? Trial Comparing Preoperative Chemoradiotherapy (Paclitaxel and Carboplatin) Followed by Surgery to Surgery Followed by Postoperative Chemoradiotherapy (Paclitaxel and Carboplatin) for Esophageal Cancer.
Dana-Farber Cancer Institute - Recruiting 18 years or older. - Randomized, Double-Blind, Placebo Controlled Phase II Study of FOLFOX +/- Ziv-Aflibercept in Patients With Advanced Esophageal and Gastric Cancer.
Peking University - Recruiting 18 years to 75 years. - Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer.
S-1 and Paclitaxel; Paclitaxel and Cisplatin; 5-FU and Cisplatin
Zhejiang Cancer Hospital - Recruiting 18 years to 70 years. - A Prospective, Single Arm, Multicenter, Phase II Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
Nimotuzumab combined with paclitaxel and cisplatin
Sun Yat-sen University - Recruiting 18 years to 65 years. - Efficacy Study of Endoscopic Ultrasound Combining With Submucosal Saline Injection for Pretreatment Staging of T1a and T1b in Patients With Early Esophageal Cancer.
Changzhou No.2 People's Hospital - Recruiting 20 years to 80 years. - A Phase II Clinical Trial on VEGF Expression Interfered by Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer.
chemoradiotherapy; thalidomide; without thalidomide
UMC Utrecht - Recruiting 18 years to 75 years. - Robot-assisted Minimally Invasive Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer. The ROBOT-trial: a Monocenter Randomized Controlled Trial..
Odense University Hospital - Recruiting 18 years or older. - Prospective, Randomized Trial of the Effects on HRQoL, Cost-Utility and Reintervention Rate, of Nurse Home Visits, in Patients With SEMS Treated Malignant Disease in the Esophagus and Cardia..
Fudan University - Recruiting 18 years to 75 years. - A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence.
Maastricht Radiation Oncology - Recruiting 18 years or older. - Consequences of Positron-Emission-Tomography/Computed Tomography (PET/CT) Based Radiotherapy Treatment Planning for Clinical Outcome in Esophageal Cancer Patients.
University of Cologne - Recruiting 18 years or older. - Prospective Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of ERCC1 in Response to Treatment With Neoadjuvant Radiochemotherapy in Patients With Esophageal Cancer.
University of Dublin, Trinity College - Recruiting 18 years to 80 years. - Randomized Double Blinded Trial to Investigate Effects of an Enteral Nutritional Supplement Enriched With Eicosapentaenoic Acid on Body Composition,Complications,Stress Response,Immune Function & Quality of Life in After Esophagectomy.
Hamamatsu University - Recruiting 20 years to 85 years. - Pharmacokinetic and Pharmacodynamic Study of S-1 and Its Effects in Patients With the Digestive Organ Cancer With Reference to Genetic Polymorphism and Activity of CYP2A6 and DPD.